Accepted for Publication: February 24, 2021.
Published Online: September 9, 2021. doi:10.1001/jamaoncol.2021.2132
Corresponding Author: Otto Metzger-Filho, MD, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (otto_metzger@dfci.harvard.edu).
Author Contributions: Dr Metzger-Filho had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Sella and Weiss served as co–first authors and contributed equally to the work.
Concept and design: Sella, Weiss, King, Pilewskie, Metzger-Filho.
Acquisition, analysis, or interpretation of data: Sella, Weiss, Mittendorf, Giuliano.
Drafting of the manuscript: Sella, Weiss, Pilewskie, Metzger-Filho.
Critical revision of the manuscript for important intellectual content: Sella, Weiss, Mittendorf, King, Pilewskie, Giuliano.
Administrative, technical, or material support: Sella, Weiss, Metzger-Filho.
Supervision: Mittendorf, King, Metzger-Filho.
Conflict of Interest Disclosures: Dr Sella reported personal fees from Roche outside the submitted work, is a Goldfarb Advanced Fellow in breast oncology at the Dana-Farber Cancer Institute, and is also supported by the American Physicians Fellowship for Medicine in Israel and the Pinchas Burstein Talpiot Medical Leadership Program. Dr Weiss reported a sponsored research agreement with Myriad Laboratories Inc unrelated to the current work. Dr Mittendorf reported honoraria from Physician Education Resource; personal fees from serving on scientific advisory boards for Exact Sciences (formerly Genomic Health), Merck, and Roche/Genentech; grants from Roche/Genentech via a Stand Up to Cancer grant; funding through a sponsored research agreement from GlaxoSmithKline; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and additional support as the Rob and Karen Hale Distinguished Chair in Surgical Oncology. Dr King reported receiving speaker honoraria from and personal fees for serving on the advisory board for Exact Sciences (formerly Genomic Health). Dr Metzger-Filho reported institutional research funding from Pfizer, Roche/Genentech, Abbvie, the Breast Cancer Research Foundation, and the Maor Foundation, as well as funding from serving on the advisory board at GI Therapeutics, outside the submitted work. No other disclosures were reported.
Meeting Presentation: This work was presented at the San Antonio Breast Cancer Symposium; December 10, 2019; San Antonio, Texas.
1.Morgan
J , Wyld
L , Collins
KA , Reed
MW . Surgery versus primary endocrine therapy for elderly women with operable primary breast cancer.
Cochrane Database Syst Rev. 2014;(5).
Google Scholar 2.Eiermann
W , Paepke
S , Appfelstaedt
J ,
et al; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study.
Ann Oncol. 2001;12(11):1527-1532. doi:
10.1023/A:1013128213451
PubMedGoogle ScholarCrossref 3.Smith
IE , Dowsett
M , Ebbs
SR ,
et al; IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
J Clin Oncol. 2005;23(22):5108-5116. doi:
10.1200/JCO.2005.04.005
PubMedGoogle ScholarCrossref 4.Cataliotti
L , Buzdar
AU , Noguchi
S ,
et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial.
Cancer. 2006;106(10):2095-2103. doi:
10.1002/cncr.21872
PubMedGoogle ScholarCrossref 7.Semiglazov
VF , Semiglazov
VV , Dashyan
GA ,
et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Cancer. 2007;110(2):244-254. doi:
10.1002/cncr.22789
PubMedGoogle ScholarCrossref 8.Cardoso
F , Kyriakides
S , Ohno
S ,
et al; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2019;30(10):1674. doi:
10.1093/annonc/mdz189
PubMedGoogle ScholarCrossref 10.Dietz
JR , Moran
MS , Isakoff
SJ ,
et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
Breast Cancer Res Treat. 2020;181(3):487-497. doi:
10.1007/s10549-020-05644-z
PubMedGoogle ScholarCrossref 13.von Minckwitz
G , Untch
M , Blohmer
J-U ,
et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
J Clin Oncol. 2012;30(15):1796-1804. doi:
10.1200/JCO.2011.38.8595
PubMedGoogle ScholarCrossref 14.Ellis
MJ , Suman
VJ , Hoog
J ,
et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031.
J Clin Oncol. 2011;29(17):2342-2349. doi:
10.1200/JCO.2010.31.6950
PubMedGoogle ScholarCrossref 16.Ellis
MJ , Coop
A , Singh
B ,
et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol. 2001;19(18):3808-3816. doi:
10.1200/JCO.2001.19.18.3808
PubMedGoogle ScholarCrossref 17.Ma
CX , Suman
VJ , Leitch
AM ,
et al. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
J Clin Oncol. 2020;38(suppl 15):504. doi:
10.1200/JCO.2020.38.15_suppl.504
Google ScholarCrossref 19.Kalinsky
K , Barlow
WE , Meric-Bernstam
F ,
et al. GS3-00. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/− chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤25: SWOG S1007 (RxPonder). Abstract presented at: San Antonio Breast Cancer Symposium; December 10, 2020. Accessed August 5, 2021.
https://www.abstractsonline.com/pp8/#!/9223/presentation/2794 21.Bear
HD , Wan
W , Robidoux
A ,
et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial.
J Surg Oncol. 2017;115(8):917-923. doi:
10.1002/jso.24610
PubMedGoogle ScholarCrossref 22.Barker
AD , Sigman
CC , Kelloff
GJ , Hylton
NM , Berry
DA , Esserman
LJ . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
Clin Pharmacol Ther. 2009;86(1):97-100. doi:
10.1038/clpt.2009.68
PubMedGoogle ScholarCrossref 23.Gianni
L , Zambetti
M , Clark
K ,
et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
J Clin Oncol. 2005;23(29):7265-7277. doi:
10.1200/JCO.2005.02.0818
PubMedGoogle ScholarCrossref 24.Whitworth
P , Beitsch
P , Mislowsky
A ,
et al. Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective Neoadjuvant Breast Registry Symphony trial (NBRST) predicted by molecular subtyping.
Ann Surg Oncol. 2017;24(3):669-675. doi:
10.1245/s10434-016-5600-x
PubMedGoogle ScholarCrossref 25.Ueno
T , Masuda
N , Yamanaka
T ,
et al. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Int J Clin Oncol. 2014;19(4):607-613. doi:
10.1007/s10147-013-0614-x
PubMedGoogle ScholarCrossref 27.Iwata
H , Masuda
N , Yamamoto
Y ,
et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat. 2019;173(1):123-133. doi:
10.1007/s10549-018-4964-y
PubMedGoogle ScholarCrossref 30.Torrisi
R , Bagnardi
V , Pruneri
G ,
et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Br J Cancer. 2007;97(6):802-808. doi:
10.1038/sj.bjc.6603947
PubMedGoogle ScholarCrossref 31.Shimizu
D , Ishikawa
T , Tanabe
M ,
et al. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
Breast Cancer. 2014;21(5):557-562. doi:
10.1007/s12282-012-0429-z
PubMedGoogle ScholarCrossref 32.Masuda
N , Sagara
Y , Kinoshita
T ,
et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Lancet Oncol. 2012;13(4):345-352. doi:
10.1016/S1470-2045(11)70373-4
PubMedGoogle ScholarCrossref 33.Alba
E , Calvo
L , Albanell
J ,
et al; GEICAM. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Ann Oncol. 2012;23(12):3069-3074. doi:
10.1093/annonc/mds132
PubMedGoogle ScholarCrossref 34.Kim
HJ , Noh
WC , Lee
ES ,
et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Breast Cancer Res. 2020;22(1):54. doi:
10.1186/s13058-020-01288-5
PubMedGoogle ScholarCrossref 35.Dellapasqua
S , Gray
KP , Munzone
E ,
et al; International Breast Cancer Study Group. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial.
J Clin Oncol. 2019;37(5):386-395. doi:
10.1200/JCO.18.00296
PubMedGoogle ScholarCrossref 36.Llombart-Cussac
A , Guerrero
Á , Galán
A ,
et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Clin Transl Oncol. 2012;14(2):125-131. doi:
10.1007/s12094-012-0771-9
PubMedGoogle ScholarCrossref 38.Mlineritsch
B , Tausch
C , Singer
C ,
et al; Austrian Breast, Colorectal Cancer Study Group (ABCSG). Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Breast Cancer Res Treat. 2008;112(1):203-213. doi:
10.1007/s10549-007-9843-x
PubMedGoogle ScholarCrossref 40.Baselga
J , Semiglazov
V , van Dam
P ,
et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
J Clin Oncol. 2009;27(16):2630-2637. doi:
10.1200/JCO.2008.18.8391
PubMedGoogle ScholarCrossref 41.Fasching
PA , Jud
SM , Hauschild
M ,
et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
BMC Cancer. 2014;14:66. doi:
10.1186/1471-2407-14-66
PubMedGoogle ScholarCrossref 42.Fontein
DBY , Charehbili
A , Nortier
JWR ,
et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients—a phase II trial.
Eur J Cancer. 2014;50(13):2190-2200. doi:
10.1016/j.ejca.2014.05.010
PubMedGoogle ScholarCrossref 43.Guarneri
V , Generali
DG , Frassoldati
A ,
et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
J Clin Oncol. 2014;32(10):1050-1057. doi:
10.1200/JCO.2013.51.4737
PubMedGoogle ScholarCrossref 44.Lerebours
F , Rivera
S , Mouret-Reynier
M-A ,
et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Cancer. 2016;122(19):3032-3040. doi:
10.1002/cncr.30143
PubMedGoogle ScholarCrossref 45.Johnston
S , Puhalla
S , Wheatley
D ,
et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial.
J Clin Oncol. 2019;37(3):178-189. doi:
10.1200/JCO.18.01624
PubMedGoogle ScholarCrossref 46.Skriver
SK , Laenkholm
A-V , Rasmussen
BB ,
et al. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Acta Oncol. 2018;57(1):31-37. doi:
10.1080/0284186X.2017.1401228
PubMedGoogle ScholarCrossref 47.Mayer
IA , Prat
A , Egle
D ,
et al. A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB).
Clin Cancer Res. 2019;25(10):2975-2987. doi:
10.1158/1078-0432.CCR-18-3160
PubMedGoogle ScholarCrossref 48.Saura
C , Hlauschek
D , Oliveira
M ,
et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2019;20(9):1226-1238. doi:
10.1016/S1470-2045(19)30334-1
PubMedGoogle ScholarCrossref 49.Ellis
MJ , Tao
Y , Luo
J ,
et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
J Natl Cancer Inst. 2008;100(19):1380-1388. doi:
10.1093/jnci/djn309
PubMedGoogle ScholarCrossref 51.Preusser
M , De Mattos-Arruda
L , Thill
M ,
et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
ESMO Open. 2018;3(5):e000368. doi:
10.1136/esmoopen-2018-000368
PubMedGoogle Scholar 52.Prat
A , Saura
C , Pascual
T ,
et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol. 2020;21(1):33-43. doi:
10.1016/S1470-2045(19)30786-7
PubMedGoogle ScholarCrossref 53.Chow
LWC , Morita
S , Chow
CYC , Ng
W-K , Toi
M . Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value.
Endocr Relat Cancer. 2018;25(2):123-130. doi:
10.1530/ERC-17-0396
PubMedGoogle ScholarCrossref 54.Ma
CX , Gao
F , Luo
J ,
et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer.
Clin Cancer Res. 2017;23(15):4055-4065. doi:
10.1158/1078-0432.CCR-16-3206
PubMedGoogle ScholarCrossref 55.Hurvitz
SA , Martin
M , Press
MF ,
et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR
+/HER2
- breast cancer.
Clin Cancer Res. 2020;26(3):566-580. doi:
10.1158/1078-0432.CCR-19-1425
PubMedGoogle ScholarCrossref 60.Hieken
TJ , Boughey
JC , Jones
KN , Shah
SS , Glazebrook
KN . Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Ann Surg Oncol. 2013;20(10):3199-3204. doi:
10.1245/s10434-013-3118-z
PubMedGoogle ScholarCrossref 61.Palmieri
C , Cleator
S , Kilburn
LS ,
et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.
Breast Cancer Res Treat. 2014;148(3):581-590. doi:
10.1007/s10549-014-3183-4
PubMedGoogle ScholarCrossref 62.Montagna
G , Sevilimedu
V , Fornier
M , Jhaveri
K , Morrow
M , Pilewskie
ML . How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery?
Ann Surg Oncol. 2020;27(12):4702-4710. doi:
10.1245/s10434-020-08888-7
PubMedGoogle ScholarCrossref 66.Smith
I , Robertson
J , Kilburn
L ,
et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol. 2020;21(11):1443-1454. doi:
10.1016/S1470-2045(20)30458-7
PubMedGoogle ScholarCrossref 67.Dowsett
M , Smith
IE , Ebbs
SR ,
et al; IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
J Natl Cancer Inst. 2007;99(2):167-170. doi:
10.1093/jnci/djk020
PubMedGoogle ScholarCrossref 68.Ellis
MJ , Suman
VJ , Hoog
J ,
et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
J Clin Oncol. 2017;35(10):1061-1069. doi:
10.1200/JCO.2016.69.4406
PubMedGoogle ScholarCrossref 70.Harris
LN , Ismaila
N , McShane
LM ,
et al; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2016;34(10):1134-1150. doi:
10.1200/JCO.2015.65.2289
PubMedGoogle ScholarCrossref 73.Giuliano
AE , Hunt
KK , Ballman
KV ,
et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
JAMA. 2011;305(6):569-575. doi:
10.1001/jama.2011.90
PubMedGoogle ScholarCrossref 74.Harbeck
N , Gluz
O , Kuemmel
S ,
et al. Abstract GS4-04:Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: primary outcome analysis from the WSG-ADAPT HR+/HER2- trial. Abstract presented at: San Antonio Breast Cancer Symposium; December 11, 2020. Accessed August 5, 2021.
https://cancerres.aacrjournals.org/content/81/4_Supplement/GS4-04 75.Johnston
SRD , Harbeck
N , Hegg
R ,
et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE).
J Clin Oncol. 2020;38(34):3987-3998. doi:
10.1200/JCO.20.02514
PubMedGoogle ScholarCrossref